These data indicate that IL-10 may be responsible for the inhibition of TLR4-triggered activation of the NF-κb/MAPKs pathways in MS-treated macrophages, which contributes to the reduced production of pro-inflammatory cytokines induced by LPS. This evidence concerns the gene TLR4 and myeloid sarcoma.